1. Transcatheter closure of congenital ventricular septal defects using the Amplatzer Duct Occluder II device: preliminary data from a Tunisian monocentric study.
- Author
-
Slim M, Ben Farhat S, Ben Ouannes S, Chrigui R, Yahia F, Thabet H, Ghardallou H, Gribaa R, ElHraiech A, and Neffati E
- Subjects
- Cardiac Catheterization adverse effects, Cardiac Catheterization methods, Child, Female, Humans, Male, Preliminary Data, Retrospective Studies, Treatment Outcome, Heart Septal Defects, Ventricular surgery, Septal Occluder Device
- Abstract
Introduction: Percutaneous closure of congenital ventricular septal defects (VSDs) represents a promising alternative to surgery with lower rate of complications and shorter hospital stay. Its main limitation is the choice of the appropriate device for each type of defect., Aim: To report the experience of the service of cardiology (Sahloul hospital, Sousse, Tunisia) in percutaneous closure of congenital VSDs with Amplatzer Duct Occluder II (ADOII)., Methods: This was a retrospective, monocentric study, conducted from January 2013 to December 2017. The study included patients treated by percutaneous closure of congenital VSDs with the ADOII device., Results: Twelve patients (6 boys; 6 girls) were included. The mean±SD of patients' age and weight were 65±41 months and 23±10 kg, respectively. VSDs were peri-membranous (n=9) and muscular (n=3), and defects were restrictive (n=11) and non-restrictive (n=1). The mean (minimum-maximum) size of VSDs was 4.72 (3-6) mm. Eleven ADOII prostheses were successfully implanted. One failure procedure was noted with migration of the device into the pulmonary artery. A second child with perimembranous defect developed transient atrioventricular block. No deaths occurred., Conclusion: The present early experience shows that percutaneous closure with ADOII device of perimembranous and trabecular VSDs is safe and effective.
- Published
- 2022